Coelho Rogerio Vivaldi - Nov 4, 2021 Form 4 Insider Report for Sigilon Therapeutics, Inc. (SGTX)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Stock symbol
SGTX
Transactions as of
Nov 4, 2021
Transactions value $
$0
Form type
4
Date filed
11/5/2021, 04:15 PM
Next filing
Jan 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGTX Common Stock Award $0 +50K +213.12% $0.00 73.5K Nov 4, 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units set forth in this table vests as to 20% on the first anniversary of the date of grant, 20% on the second anniversary of the date of grant, and 60% on the third anniversary of the date of grant, subject to the grantee's continued service to the Company on each vesting date.
F2 Includes 1,239 shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the purchase period of April 1, 2021 to September 30, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on September 30, 2021. This transaction is exempt under Rule 16b-3(c).